Role of liver biopsy in hepatocellular carcinoma

被引:110
作者
Di Tommaso, Luca [1 ,2 ]
Spadaccini, Marco [2 ]
Donadon, Matteo [2 ,3 ]
Personeni, Nicola [2 ,4 ]
Elamin, Abubaker [1 ]
Aghemo, Alessio [2 ,5 ]
Lleo, Ana [2 ,5 ]
机构
[1] Humanitas Clin & Res Ctr IRCCS, Pathol Unit, I-20089 Rozzano, Italy
[2] Humanitas Univ, Dept Biomed Sci, I-20090 Pieve Emanuele, Italy
[3] Humanitas Clin & Res Ctr IRCCS, Dept Gen Surg, Div Hepatobiliary & Gen Surg, I-20089 Rozzano, Italy
[4] Humanitas Clin & Res Ctr IRCCS, Humanitas Canc Ctr, Div Med Oncol & Hematol, I-20089 Rozzano, Italy
[5] Humanitas Clin & Res Ctr IRCCS, Dept Gastroenterol, Div Internal Med & Hepatol, I-20089 Rozzano, Italy
关键词
Hepatocellular carcinoma; Liver biopsy; Prognostic factors; Liver cancer; Recurrence; Liquid biopsy; MASS-FORMING CHOLANGIOCARCINOMA; CLINICAL-PRACTICE GUIDELINES; NEEDLE TRACT IMPLANTATION; CHRONIC HEPATITIS-B; INTRAHEPATIC CHOLANGIOCARCINOMA; ENHANCEMENT PATTERNS; RISK-FACTORS; PERIPHERAL CHOLANGIOCARCINOMA; PROGNOSTIC-SIGNIFICANCE; NONINVASIVE DIAGNOSIS;
D O I
10.3748/wjg.v25.i40.6041
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The role of liver biopsy in the diagnosis of hepatocellular carcinoma (HCC) has been challenged over time by the ability of imaging techniques to characterize liver lesions in patients with known cirrhosis. In fact, in the diagnostic algorithm for this tumor, histology is currently relegated to controversial cases. Furthermore, the risk of complications, such as tumor seeding and bleeding, as well as inadequate sampling have further limited the use of liver biopsy for HCC management. However, there is growing evidence of prognostic and therapeutic information available from microscopic and molecular analysis of HCC and, as the information content of the tissue sample increases, the advantages of liver biopsy might modify the current risk/benefit ratio. We herein review the role and potentiality of liver biopsy in the diagnosis and management of HCC. As the potentiality of precision medicine comes to the management of HCC, it will be crucial to have rapid pathways to define prognosis, and even treatment, by identifying the patients who could most benefit from target-driven therapies. All of the above reasons suggest that the current role of liver biopsy in the management of HCC needs substantial reconsideration.
引用
收藏
页码:6041 / 6052
页数:12
相关论文
共 115 条
[1]  
Ahn Dong-Won, 2011, Korean J Hepatol, V17, P106, DOI 10.3350/kjhep.2011.17.2.106
[2]   The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015 [J].
Akinyemiju, Tomi ;
Abera, Semaw ;
Ahmed, Muktar ;
Alam, Noore ;
Alemayohu, Mulubirhan Assefa ;
Allen, Christine ;
Al-Raddadi, Rajaa ;
Alvis-Guzman, Nelson ;
Amoako, Yaw ;
Artaman, Al ;
Ayele, Tadesse Awoke ;
Barac, Aleksandra ;
Bensenor, Isabela ;
Berhane, Adugnaw ;
Bhutta, Zulfiqar ;
Castillo-Rivas, Jacqueline ;
Chitheer, Abdulaal ;
Choi, Jee-Young ;
Cowie, Benjamin ;
Dandona, Lalit ;
Dandona, Rakhi ;
Dey, Subhojit ;
Dicker, Daniel ;
Phuc, Huyen ;
Ekwueme, Donatus U. ;
Zaki, Maysaa El Sayed ;
Fischer, Florian ;
Furst, Thomas ;
Hancock, Jamie ;
Hay, Simon I. ;
Hotez, Peter ;
Jee, Sun Ha ;
Kasaeian, Amir ;
Khader, Yousef ;
Khang, Young-Ho ;
Kumar, G. Anil ;
Kutz, Michael ;
Larson, Heidi ;
Lopez, Alan ;
Lunevicius, Raimundas ;
Malekzadeh, Reza ;
McAlinden, Colm ;
Meier, Toni ;
Mendoza, Walter ;
Mokdad, Ali ;
Moradi-Lakeh, Maziar ;
Nagel, Gabriele ;
Nguyen, Quyen ;
Nguyen, Grant ;
Ogbo, Felix .
JAMA ONCOLOGY, 2017, 3 (12) :1683-1691
[3]   Cost Effectiveness of Alternative Surveillance Strategies for Hepatocellular Carcinoma in Patients With Cirrhosis [J].
Andersson, Karin L. ;
Salomon, Joshua A. ;
Goldie, Sue J. ;
Chung, Raymond T. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2008, 6 (12) :1418-1424
[4]  
[Anonymous], HEPATOLOGY
[5]   Characterization of small nodules in cirrhosis by assessment of vascularity: The problem of hypovascular hepatocellular carcinoma [J].
Bolondi, L ;
Gaiani, S ;
Celli, N ;
Goffieri, R ;
Grigioni, WF ;
Leoni, S ;
Venturi, AM ;
Piscaglia, F .
HEPATOLOGY, 2005, 42 (01) :27-34
[6]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[7]   Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[8]   Hepatocellular carcinoma: clinical frontiers and perspectives [J].
Bruix, Jordi ;
Gores, Gregory J. ;
Mazzaferro, Vincenzo .
GUT, 2014, 63 (05) :844-855
[9]   EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies [J].
Cai, Mu-Yan ;
Tong, Zhu-Ting ;
Zheng, Fang ;
Liao, Yi-Ji ;
Wang, Yi ;
Rao, Hui-Lan ;
Chen, Yang-Chao ;
Wu, Qiu-Liang ;
Liu, Yan-Hui ;
Guan, Xin-Yuan ;
Lin, Marie C. ;
Zeng, Yi-Xin ;
Kung, Hsiang-Fu ;
Xie, Dan .
GUT, 2011, 60 (07) :967-976
[10]   Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification [J].
Calderaro, Julien ;
Couchy, Gabrielle ;
Imbeaud, Sandrine ;
Amaddeo, Giuliana ;
Letouze, Eric ;
Blanc, Jean-Frederic ;
Laurent, Christophe ;
Hajji, Yacine ;
Azoulay, Daniel ;
Bioulac-Sage, Paulette ;
Nault, Jean-Charles ;
Zucman-Rossi, Jessica .
JOURNAL OF HEPATOLOGY, 2017, 67 (04) :727-738